#United States #San Diego #Jazz Pharmaceuticals #Actio Biosciences #ABS-1230

Jazz Pharmaceuticals Strengthens Rare Epilepsy Portfolio with Acquisition of Actio Biosciences

In a significant business move, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced its acquisition of Actio Biosciences, Inc. for a total consideration of $820 million upfront, with an additional $500 million contingent on approval milestones. This strategic acquisition enhances Jazz’s position in the rapidly evolving field of rare epilepsies, focusing on conditions with significant unmet medical needs.

Highlighting ABS-1230

A pivotal element of this acquisition is Actio's lead compound, ABS-1230, which is under development as a first-in-class small molecule therapy targeting KCNT1+ epilepsy. This form of epilepsy is particularly devastating, affecting approximately 2,500 patients in the United States. The disease often leads to debilitating seizures and profound developmental delays, significantly diminishing the quality of life for those affected. With 80% of patients experiencing the onset of seizures in infancy, the need for effective treatments has never been more urgent.

Currently, there are no FDA-approved therapies for KCNT1+ epilepsy, making ABS-1230 a potentially groundbreaking solution. Early clinical trials have shown promising results, indicating meaningful reductions in seizure frequency among children receiving this innovative therapy. This positive early data supports Jazz's interest in pursuing ABS-1230 as a viable option for patients in desperate need of treatment.

Strengthening Leadership in Rare Epilepsy

With this acquisition, Jazz aims to reinforce its leadership in the rare epilepsy segment. The company's existing portfolio includes Epidiolex, another well-regarded therapy for epilepsy, which has had significant commercial success. Renee Gala, CEO of Jazz Pharmaceuticals, expressed the company’s commitment to building on this foundation by incorporating ABS-1230, thereby addressing the critical needs of the epilepsy community.

“We are excited to implement the development expertise and commercial strength of Jazz to bring this important medicine to children and families who currently have no options,” said Gala.

Following the acquisition, Jazz anticipates collaborating closely with Actio's team to accelerate the drug's development, aiming for timely delivery to those affected by this catastrophic condition.

Financial and Strategic Aspects of the Deal

The terms of the agreement include an upfront payment of $820 million to Actio shareholders, with potential additional payments linked to milestones in sales and drug approvals that could total up to $500 million. As part of the transition, Actio will create a new, independently-held entity, maintaining a focus on genetic rare neurological diseases, which will pursue the development of other promising therapies.

This strategic decision aligns with Jazz Pharmaceuticals' long-term vision of becoming a leading innovator in the field of rare diseases where therapeutic options are limited. By investing in Actio's pipeline, which includes various genetic therapies, Jazz will expand its therapeutic arsenal, potentially addressing other prevalent genetic epilpetic disorders as well.

The Future for KCNT1-related Epilepsy

The need for effective treatments for KCNT1-related epilepsy cannot be overstated. Patients with this condition often experience treatment-resistant seizures, requiring a fresh approach to therapy. ABS-1230 not only promises an innovative treatment pathway but also presents the possibility of addressing additional genetic epilepsy indications in the future. Given its FDA Fast Track designation and acceptance into the Rare Disease Evidence Principles program, the trajectory for ABS-1230's development looks very promising.

In summary, Jazz’s acquisition of Actio Biosciences is set to reshape its future in the healthcare landscape, paving the way for innovative solutions for patients grappling with rare epilepsy types. By harnessing Actio's therapeutic focus and Jazz’s established market presence, there is hope for transformative advancements that can significantly improve the lives of those affected by these debilitating conditions.